Log in

NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

$10.42
-0.07 (-0.67 %)
(As of 01/19/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.35
Now: $10.42▼
$10.64
50-Day Range
$7.31
MA: $8.82▼
$10.50
52-Week Range
$5.36
Now: $10.42▼
$17.83
Volume96,230 shs
Average Volume152,943 shs
Market Capitalization$248.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
Previous Symbol
CUSIPN/A
CIK1367920
Webhttp://www.concertpharma.com/
Phone781-860-0045

Debt

Debt-to-Equity Ratio0.14
Current Ratio9.53
Quick Ratio9.53

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.51 million
Price / Sales23.64
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.16 per share
Price / Book1.46

Profitability

EPS (Most Recent Fiscal Year)($2.40)
Net Income$-56,020,000.00
Net Margins-7,291.37%
Return on Equity-55.06%
Return on Assets-45.23%

Miscellaneous

Employees71
Outstanding Shares23,840,000
Market Cap$248.41 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:CNCE Rates by TradingView

(Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.72) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.85) by $0.13. The biotechnology company earned $0.01 million during the quarter, compared to the consensus estimate of $0.35 million. Concert Pharmaceuticals had a negative return on equity of 55.06% and a negative net margin of 7,291.37%. View Concert Pharmaceuticals' Earnings History.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Concert Pharmaceuticals.

What price target have analysts set for CNCE?

7 equities research analysts have issued 1 year price objectives for Concert Pharmaceuticals' shares. Their forecasts range from $8.00 to $25.00. On average, they anticipate Concert Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 63.1% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

What is the consensus analysts' recommendation for Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $29/share is comprised of $10.39 from CTP-543 in AA + $3.81 from AVP-786 in AD + $8.60 in schizophrenia + $5.75 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/2/2019)

Has Concert Pharmaceuticals been receiving favorable news coverage?

Media stories about CNCE stock have been trending negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Concert Pharmaceuticals earned a news impact score of -2.5 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Concert Pharmaceuticals.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (6.15%) and Steward Partners Investment Advisory LLC (0.32%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt and Richard Aldrich. View Institutional Ownership Trends for Concert Pharmaceuticals.

Which institutional investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van and Richard Aldrich. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $10.42.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $248.41 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  444 (Vote Outperform)
Underperform Votes:  366 (Vote Underperform)
Total Votes:  810
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Balanced Fund
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel